Form DEFR14A - Revised definitive proxy soliciting materials:
SEC Accession No. 0001628280-17-002720
Filing Date
2017-03-20
Accepted
2017-03-20 17:27:42
Documents
9
Effectiveness Date
2017-03-20

Document Format Files

Seq Description Document Type Size
1 DEFR14A def-r2017proxystatement.htm DEFR14A 684144
2 EXHIBIT 99.1 def-r2017additionaldefinit.htm EX-99.1 45576
3 ajbackgroundpicture.jpg GRAPHIC 10605
4 cumberlandlogo.jpg GRAPHIC 12534
5 cumberlandlogoa02a01.jpg GRAPHIC 12534
6 cumberlandpharmalogoa01.jpg GRAPHIC 37721
7 internetimage.jpg GRAPHIC 8352
8 untitleda01a01.jpg GRAPHIC 9167
9 xa01.jpg GRAPHIC 2405
  Complete submission text file 0001628280-17-002720.txt   854700
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: DEFR14A | Act: 34 | File No.: 001-33637 | Film No.: 17702350
SIC: 2834 Pharmaceutical Preparations